Start with the action FDA actually took
On June 10, FDA said it approved changes to the Drug Facts label for OTC alli (orlistat) 60 mg capsules. The revised label warns about rare acute kidney injury and advises consumers with a history of kidney disease or kidney stones to ask a health care provider before use. FDA also lists symptoms that should lead a consumer to stop the product and seek medical guidance.
FDA said the change aligns kidney-risk language across approved orlistat products, including prescription-strength Xenical. Keep the action in proportion: this was a labeling change, not a recall, market withdrawal, or conclusion that every person who uses orlistat will experience kidney harm.
The case signal matters, and so do its limits
FDA identified 12 cases of kidney complications associated with alli use in its adverse-event system and the medical literature. The median patient age was 61; eight cases involved hospitalization and five involved dialysis. That severity explains why the signal deserves attention. The case count is not an incidence rate.
The agency also described substantial uncertainty. Reports may be incomplete, outcomes were missing in some cases, and several people had other possible reasons for kidney problems, including obesity, diabetes, high blood pressure, or a history of kidney disease or stones. The communication can prompt a resident-specific clinical review; a medication-list match cannot establish causation.
First make the nonprescription use visible
Alli is available without a prescription, so a list built only from dispensing claims or prescription orders may omit it. That is an operational inference, not an FDA finding. It is still worth testing: compare a facility's documented OTC and self-administered products with the information available to the consultant pharmacist.
If current orlistat use appears, confirm the product, strength, information source, and record date. Then route the FDA communication and the resident-specific question through the facility's established clinical process. Do not quietly discontinue a product, add a diagnosis, or turn an alert into an automatic recommendation without assessment by the responsible clinician.
Run a small, bounded capture test
Choose a small sample. For each nonprescription product, record how it entered the medication history, who confirmed current use, and when it was last reconciled. If the practice relies on a pharmacy or facility feed, document what the feed includes and where resident-reported or facility-supplied products must be added.
Preserve the safety-review trail as well: source notice, resident context, question, recipient, response, and next action. Software can help people find and follow those steps. It cannot establish causation, choose treatment, or prove that the medication history is complete.
Finish by giving the permitted record to an authorized reviewer who did not assemble it. Can that person identify the product, see when use was confirmed, find the FDA source, distinguish the safety signal from an individual conclusion, and locate the responsible clinician's response and next step? Record each missing link. This does not validate the medication history or clinical decision; it tests whether another person can safely understand the work already documented.